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Abstract: Tobacco use is inextricably linked to a number of health risks both in the 
general and HIV-infected populations. There is, however, a dearth of research on effective 
tobacco control programs among people living with HIV, and especially among adolescents, 
young adults and pregnant women, groups with heightened or increased vulnerability 
secondary to tobacco use. Adolescents and young adults constitute a growing population of 
persons living with HIV infection. Early and continued tobacco use in this population 
living with a disease characterized by premature onset multimorbidity and chronic 
inflammation is of concern. Additionally, there is an increased acuity for tobacco control 
among HIV-infected pregnant women to reduce pregnancy morbidity and improve fetal 
outcome. This review will provide an important summary of current knowledge of tobacco 
use among HIV-infected adolescents, young adults and pregnant women. The effects of 
tobacco use in these specific populations will be presented and the current state of tobacco 
control within these populations, assessed. 
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1. Introduction 
It is estimated that over 1.1 million people are living with HIV/AIDS in the United States [1] of 
whom 25% are women and 6% adolescents and young adults aged 13–24 years [2]. In 2009, 20% of 
newly diagnosed HIV-infected persons were aged 13–24 years [3]. Among women infected with HIV, 
approximately 75% are estimated to be in the reproductive age group (13–44 years) [4]. The mortality 
rate associated with HIV infection has significantly declined since the introduction of highly active 
antiretroviral therapy (HAART) [5,6], although still remains higher than that of the general population 
and life expectancy slightly lower [7–9]. HIV-infected persons in contemporary outpatient care are 
more likely to die from non-AIDS-defining illnesses (NADI) such as cardiovascular and cancer-related 
deaths, than AIDS-defining illnesses [10,11]. The occurrence of NADIs across all CD4 cell counts and 
level of viral suppression [12] suggests that other mechanisms apart from immunosuppression 
contribute to this excess mortality. The chronic inflammation associated with HIV infection has been 
thought to significantly contribute to the development of NADIs [13–15]. Co-infection with hepatitis C, 
viral latency, and microbial gut translocation are some of the conditions that contribute to  
HIV-associated persistent inflammation [16]. Regardless, behavioral factors play a fundamental role, 
and of those, tobacco use may be among the most important.  
At present, tobacco use is the leading cause of preventable mortality and morbidity and premature 
death in the United States [17,18]. It is also a major cause of preventable infant mortality and 
morbidity in the US and other industrialized countries [19]. Among HIV-uninfected adults, the 
prevalence of tobacco use is 19% (Table 1) and more common among those aged 18–44 years, without 
a Bachelor’s degree, who are uninsured, and who belong to poorer families [18,20]. The prevalence of 
tobacco use is 50–70% in the HIV-infected population, 2–3 times higher than the general  
population [21,22] (Table 1), and is also more common among younger persons (median age  
35 years) [23] with lower socio-economic status [24]. 
Table 1. A comparison of the prevalence of tobacco use between HIV-infected and general population. 
Groups General population HIV-infected 




4% (HIV acquired vertically) [25]  
39% (HIV acquired behaviorally) [26]  
21% (over-all estimate) [27]  
Pregnant women 5–36% (over-all 14%) [28] 
40–54% (before 1998) [29,30]  
14% (after 1997) [31]  
There is now evidence to suggest that the use of tobacco among adolescents and young adults is 
associated with development of respiratory and cardiovascular problems that serve as precursors to 
more long term and chronic diseases in late adulthood [18]. Thus, the higher prevalence of tobacco use 
among HIV-infected adolescents and young adults is alarming as HIV infection, itself, has also been 
associated with early-onset multimorbidity [32]. Tobacco use during pregnancy is associated with 
significant maternal and fetal morbidity and mortality. Furthermore, tobacco use increases the risk of 
vertical transmission of HIV infection, independent of maternal disease status and use of other 
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substances [30]. Therefore, there is a critical need to address tobacco use among these vulnerable  
HIV-infected groups and to ensure that effective tobacco control strategies are implemented. 
At present, the combination of behavioral modification through counseling and pharmacotherapy is 
the mainstay of tobacco control programs in the general population [33]. There are a dearth of studies 
that support the effectiveness of these well-established strategies among persons living with 
HIV/AIDS. In fact, there are currently no studies among HIV-infected adolescents and pregnant 
women. The studies among HIV-infected adults that have been published so far have found that these 
conventional approaches to tobacco control are suboptimal in the HIV-infected population [34].  
HIV-infected persons frequently have additional comorbidities that make tobacco cessation 
particularly challenging, including alcohol and illicit drug use and psychological stressors [35]. Failure 
to promote an effective tobacco control program in this high risk population is concerning as the 
mortality and morbidity benefits of tobacco cessation are undisputable [36]. Among persons living 
with HIV/AIDS, cessation of tobacco use was associated with a reduction in the adjusted incidence 
rate ratio for the development of cardiovascular disease from 2.32 to 1.49 after only three years of 
tobacco abstinence [37]. In the general population, tobacco cessation during pregnancy prevented  
5–6% of perinatal deaths, 7–10% of preterm deliveries, and 17–26% of low-birthweight births [36]. 
In this review, we first examine the epidemiology of tobacco use among both HIV-infected and 
uninfected adolescents, young adults and pregnant women. We then review the impact of tobacco use 
among HIV-infected persons and discuss different tobacco control strategies that have been studied. 
Next we look at the current state of tobacco control among adolescents, young adults and pregnant 
women in the general population. Finally, we examine how tobacco control can be addressed among 
HIV-infected adolescents, young adults and pregnant women, applying lessons derived from studies in 
the HIV-uninfected population. 
2. Epidemiology of Tobacco Use among Adolescents and Young Adults 
2.1. General Population 
Current estimates show that 88% of adult smokers in the US initiate tobacco use before 18 years [38] 
and 99% before 26 years [18]. Experimentation with tobacco peaks at age 11 to 13 years among 
adolescents and more than one third become regular habitual smokers thereafter [39]. In 2009, 23% of 
US high school students were current smokers [18] (Table 1). Among all age groups in the US,  
the highest prevalence of tobacco use is among young adults aged 18–25 years with a rate of 34% [18].  
In general, these estimates among adolescents and young adults declined from the late 1990’s but the 
rate of decline considerably diminished in the last few years. Prevalence has remained highest among 
American Indians and Alaskan Natives, and among those with low socioeconomic status [18]. 
2.2. HIV-Infected Population 
At present, there are only a few studies that address the prevalence of tobacco use among  
HIV-infected adolescents. The Reaching for Excellence in Adolescent Care and Health Project was a 
multicenter collaboration in the US that enrolled both HIV-infected and uninfected adolescents aged 
12–18 years from 1996 to 2000 [26]. HIV infection among infected adolescents was acquired through 
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high risk behavior (i.e., sexual activity, intravenous drug use) and those with vertically-transmitted 
HIV infection were excluded. HIV-uninfected adolescents with similar high risk behaviors were 
likewise recruited for comparison. In this cohort of 325 HIV-infected adolescents (26% male, 73% 
black), the over-all prevalence of tobacco use was 39% (Table 1), of whom, 27% were daily and 11% 
were weekly smokers. Fifty eight percent of HIV-infected males used tobacco (39% daily and 19% 
weekly smokers) while only 34% of females smoked (25% daily and 9% weekly smokers).  
The over-all prevalence of tobacco use among HIV-uninfected counterparts was also high at 36%.  
The rate of tobacco use among males was lower (42%) but among females, the rate was comparable 
(34%) to the HIV-infected group.  
The prevalence of tobacco use among adolescents with vertically transmitted HIV infection is 
generally lower. In a cohort of 206 HIV-infected adolescents aged 9–16 years in New York, 4% used 
tobacco (Table 1) compared with 7% of HIV-uninfected adolescents (n = 134) matched by age and 
demographics (p = 0.97) [25]. In a recent study of 266 persons aged 2–25 years, with either vertically 
or horizontally acquired HIV infection, the over-all prevalence of tobacco use was 21% (68% male, 
93% black) [27] (Table 1). Subjects who used tobacco in this study were all between 18–25 years. 
Lastly, data demonstrate a median age of 16–18 years at the time of tobacco initiation in the  
HIV-infected population [40,41].  
3. Epidemiology of Tobacco Use among Pregnant Women 
3.1. General Population 
The proportion of pregnant women in the general population who uses tobacco varies by state and 
ranges from 5% to 36% (over-all prevalence of 14%) [28] (Table 1). These estimates are plagued  
by underreporting and nondisclosure when self-report is compared to biochemical markers of tobacco 
use [42,43]. Hence, the true prevalence of tobacco use in the pregnant population is expected to be 
higher. Similar to adolescents and young adults, the prevalence is higher among younger women aged 
<25 years, American Indians and Alaskan Natives, and those with lower socioeconomic status. 
Likewise, this estimate has progressively declined in recent years [44]. 
3.2. HIV-Infected Population 
In the US, prevalence estimates for tobacco use among HIV-infected pregnant women have varied 
considerably. Estimates from the pre- and early HAART era ranged between 31–54% (Table 1).  
A survey of all liveborn deliveries from the New York State Medicaid data from 1988 to 1990 
identified a 40% prevalence of tobacco use among HIV-infected women (n = 768) during  
pregnancy [30]. Tobacco users were more likely to be white, over the age of 25 years, and 
multiparous. In a separate cohort, the Pediatric AIDS Clinical Trials Group Study 185, a multicenter 
study conducted from 1993–1997 to investigate the use zidovudine and anti-HIV immunoglobulin in 
preventing mother-to-child HIV transmission, a 31% prevalence of tobacco use was observed [45].  
On the other hand, the Women and Infants Transmission Study which enrolled a cohort of  
634 pregnant women from different centers in the US from 1990 to 1998, documented a 54% 
prevalence in their cohort [29].  
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More recent estimates match current prevalence rates in the general population. In Florida, an 
administrative data review of all HIV-infected women who delivered between 1998 and 2007 
demonstrated a 14% prevalence of tobacco use during pregnancy [31] (Table 1). Univariate analysis 
showed that pregnant smokers were more likely to be black, less than 35 years old, unmarried, and 
have no high school degree. In the Pediatric HIV/AIDS Cohort Study, an 18% prevalence of tobacco 
use was observed among 480 HIV-infected pregnant women enrolled from different centers in the  
US [46]. This study also found that self-report of tobacco use had an 86% correlation with meconium 
cotinine levels. 
It is not known why prevalence estimates of tobacco use are higher during the pre- and  
early-HAART era. It likely reflects the downward trend in the prevalence rate seen also in the general 
population which is mainly a result of more intensive campaigns against tobacco use during pregnancy 
in recent years. 
4. Impact of Tobacco Use in the HIV-Infected Population 
Tobacco use and HIV infection both lead to increased mortality risk and predispose persons to 
developing cardiovascular disease [47,48], ischemic stroke [49,50], peripheral vascular disease [51], 
lung cancer [52], cervical cancer [53,54], and osteoporosis [55,56] independent of each other. 
Although definitely multifactorial, the pathogenesis of these complications reflects certain mechanisms 
shared by both HIV infection and tobacco use (Figure 1). 
Figure 1. Through shared pathogenic mechanisms, tobacco use magnifies the independent 
association of HIV infection with cardiovascular disease, ischemic stroke, peripheral 
vascular disease, cancer, osteoporosis, and increased mortality. 
 
HIV infection is associated with persistent inflammation and immune activation that persist even 
after full virologic suppression and CD4 cell count recovery with HAART [57]. Elevated markers of 
inflammation and coagulation (i.e., interleukin 6, C-reactive protein, soluble CD14, and D-dimer) are 
predictive of higher over-all mortality and cardiovascular events [58,59] and are also believed to 
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contribute to the increased risk for atherosclerosis [60], osteoporosis [61], and cancer [62] among  
HIV-infected persons. Similarly, tobacco use also leads to chronic inflammation and platelet and 
leucocyte activation that directly facilitate atherogenesis [63], carcinogenesis [64], and development of 
osteoporosis. Furthermore, it has been shown that tobacco use heightens HIV-associated immune 
activation. Miguez-Burbano et al. demonstrated, on multivariate analysis, that HIV-infected smokers 
had demonstrably higher IL-6 levels than HIV-infected nonsmokers after adjusting for gender, use of 
HAART, stage of HIV disease and body mass index [65]. Our group also found significant association 
between elevated levels of T-cell activation (i.e., CD8+ HLA-DR+ and CD4+ HLA-DR+ T lymphocytes) 
and current tobacco use among HIV-infected persons with fully suppressed HIV-RNA for at least  
2 years [66].  
Tobacco use is directly oncogenic and causes many known malignancies including lung, colorectal, 
head and neck, pancreatic, and uterine cancer [67]. Similarly, HIV infection has been demonstrated to 
also have some oncogenic potential. Witsuba et al. demonstrated that lung cancers from HIV-infected 
persons had significantly more frequent microsatellite alterations compared with sporadic lung cancers 
from HIV-uninfected persons [68]. Impaired immune surveillance secondary to HIV-associated 
immune dysregulation is also believed to contribute to this enhanced oncogenesis [69]. 
Tobacco use also poses additional health risks to HIV-infected persons (Table 2). These include  
an increased risk for infections such as oral candidiasis [70], genital warts [71], pulmonary  
tuberculosis [72] and bacterial pneumonia [70], plus human papilloma virus related-malignancies such 
as anal and cervical cancer [73]. Tobacco use has also been associated with decreased health-related 
quality of life. Among 585 HIV-infected persons, tobacco use, independent of CD4 count, AIDS 
diagnosis, educational level, injection drug use, gender and age, was associated with lower scores for 
general health perception, physical functioning, bodily pain, energy, role functioning, and cognitive 
functioning in the Medical Outcomes Survey Scale (MOS)-HIV questionnaire [74]. There are also data 
that suggest an association with tobacco use and clinical progression of HIV infection (i.e., decline in 
CD4 count, virologic failure, occurrence of opportunistic infections), however, this finding is not 
duplicated by other studies [75].  
Table 2. Other effects of tobacco use in the HIV-infected population. 
1. Increases risk for certain infections: 
 a. Periodontal disease [76]  
 b. Hairy cell leukoplakia [70,77]  
 c. Oral candidiasis [70,78]  
 d. Warts [79]  
 e. Genital warts [71]  
 f. Tuberculosis [72]  
 g. Non-tuberculous mycobacteria [80]  
2. Increases risk for certain pulmonary diseases 
 a. Bacterial pneumonia [70,78,81]  
 b. Spontaneous pneumothorax [82,83]  
Int. J. Environ. Res. Public Health 2013, 10 2477 
 
Table 2. Cont. 
3. Increases risk for certain malignancies 
 a. Cervical cancer [84]  
 b. Anal cancer [73] 
4. Associated with increased risk of certain neuro-psychiatric symptoms 
 a. Depression [85]  
 b. AIDS Dementia Complex [78]  
5. Associated with over-all decreased quality of life [74,86] 
4.1. Impact of Tobacco Use HIV-Infected Adolescents and Young Adults 
In the general population, the disease risks associated with tobacco use among adolescents and 
young adults are similar to those in older persons. Current evidence suggests that the cardiovascular 
and respiratory risks associated with tobacco use are established early among adolescent smokers and 
serve as precursors to more chronic and serious problems later in adulthood [18]. Tobacco use among 
adolescents and young adults has been directly linked to subclinical atherosclerosis and increased 
carotid intimal thickness [87,88] as well as to early markers of vascular endothelial injury [89].  
It has also been directly associated with decreased forced expiratory volume [90] and has been shown 
to be an independent predictor of asthma, respiratory symptoms such shortness of breath and 
wheezing, and decreased exercise tolerance among adolescent smokers [91]. Since these health risks 
accumulate over time, it is expected that tobacco use established at an early age is associated with 
more adverse outcomes.  
Tobacco use also serves as a harbinger for other high risk behaviors. For example, adolescents who 
use tobacco are eight and 22 times more likely to use alcohol and cocaine, respectively, and are more 
likely to engage in other risky behaviors such as unprotected sexual intercourse, and unhealthy dieting 
techniques (i.e., ingesting dietary supplements, not eating for ≥24 h) [92,93]. Among adolescents with 
vertically-transmitted HIV infection, smokers were significantly more likely to engage in high risk 
sexual behavior including having multiple sexual partners and unprotected vaginal and anal intercourse 
compared to nonsmokers [25].  
4.2. Impact of Tobacco Use among HIV-Infected Pregnant Women 
Tobacco use during pregnancy is associated with preeclampsia, small for gestational age and low 
birth weight neonates, spontaneous pregnancy loss, stillbirth, preterm delivery, premature rupture of 
membranes, placenta previa, placental abruption, and congenital malformation [94]. In addition, 
tobacco use during and after pregnancy has been strongly associated with sudden infant death syndrome 
even after adjusting for multiple covariates including race, maternal age and parity [95]. At present, 
tobacco use during pregnancy is one of the leading causes of preventable infant mortality and 
morbidity in the US and other industrialized countries [19] and tobacco cessation during pregnancy is 
one of the strategies employed to curb infant mortality rates in these countries [96]. Maternal HIV 
infection has also been associated with adverse pregnancy outcomes including low birth weight, 
preterm birth, and intrauterine growth retardation independent of other behavioral risk factors [45].  
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With improved understanding of mother-to-child transmission of HIV infection, timely initiation of 
antiretroviral drugs, increased Caesarian delivery, and avoidance of breastfeeding when appropriate 
among infants exposed to mothers with HIV infection, vertical transmission rate has declined to only 
less than 2% [97] in industrialized countries, compared to around 25–30% without these interventions [98]. 
There are, however, studies that link tobacco use during pregnancy with increased mother-to-child 
transmission of HIV infection. Using vital statistics birth data from the New York State Medicaid 
HIV/AIDS Research Database, Turner et al. demonstrated among 768 HIV-infected pregnant women 
(42% white Hispanic, 41% black) a 45% increase in vertical transmission associated with the use of 
tobacco after adjustment for multiple risk factors that included illicit drug use, maternal clinical status, 
and delivery factors [30]. This risk may be attributed to higher incidence of premature rupture of 
membranes as well as to placental ischemia associated with tobacco use [99].  
5. Tobacco Control in the HIV-Infected Population 
The factors that negatively influence tobacco control in the general population include low 
socioeconomic status [100], existing psychiatric illness [101], and history of substance abuse [102]. 
Among people living with HIV/AIDS, these factors are more prevalent and often co-exist [24] and 
tobacco control has been a real challenge in this population. In a study of 184 HIV-infected tobacco 
users in San Francisco (82% male, 53% white), about two-thirds were unemployed and almost half had 
an annual income of below $10,000 [103]. In another study in the US, nearly half of 2,864 HIV-infected 
persons surveyed had at least one psychiatric disorder [104]. Among over 500 HIV-infected persons in 
our institution, approximately 25% had depressive or anxiety symptoms [105,106]. Furthermore, 
Cofrancesco et al. reported significantly higher rates of previous (86% versus 67%) and current  
(28% versus 16%) substance use among people living with HIV/AIDS compared with uninfected 
counterparts [107]. 
In a review of literature related to tobacco use and HIV/AIDS published from 1980 to 2008, Harris 
only found 6 studies on tobacco control interventions. The vast majority (88%) characterized the 
impact of tobacco use among people with HIV/AIDS [108]. This paper highlighted the exigency of 
conducting studies that aim to determine the best strategy to promote tobacco cessation in the  
HIV-infected population. 
We independently reviewed PUBMED and found 12 studies, published since 2000, that evaluated 
different tobacco cessation strategies (Table 3). The majority of the studies were small and 
nonrandomized. All randomized controlled trials compared conventional tobacco cessation practices 
(i.e., nicotine replacement therapy (NRT), provision of self-help materials or brief health care provider 
advice) with either cellular phone counseling (two studies), motivational intervention (three studies), 
or facilitated group treatment (one study). The abstinence rate was only significantly higher in the 
cellular phone counseling groups compared to control. There are only three studies, all small, 
nonrandomized and non-controlled, which have examined the effectiveness of newer 
pharmacotherapeutic agents, buproprion (one study) and varenicline (two studies), in the HIV-infected 
population. The results of these three studies were promising as the abstinence rate and medication 
adverse effect profile closely approximated those in the general population [109–112]. 
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Table 3. Studies on tobacco cessation in the HIV-infected population. 
Author Year Design Intervention 
Number of 
Subjects 
Follow-up Abstinence Rate 
Measure of 
Abstinence 
Wewers [113]  2000 Non-randomized NRT, weekly in-person or 
telephone counseling, skills 
training versus self-help 
materials 
Intervention: 8 
Control: not stated 
6 weeks and 8 
months 
Intervention: 62% at 6 
weeks; 50% at 8 months 
Control: 0% 6 weeks; 0% at 
8 months 
P value not provided 
Biochemical 
Lazev [114]  2003 Non-randomized Cellular phone counseling  Intervention: 20 
No control 
2 weeks 75% Self-report 
Vidrine [40]  2006 Randomized Cellular phone counseling plus 
usual care versus usual care 




3 months Intervention: 37% 
Control: 10% 
P = 0.0059 
Biochemical 




12 months Intervention: 38% 
Control: 7% 
Odds ratio: 6.2  
(CI: 2.8–14.3) 
Self-report 
Pedro-Clotet [116]  2006 Non-randomized Buproprion Intervention: 21 
No control 
12 months Intervention: 38%; no 
significant drug interactions 
Self-report 
Ingersoll [117]  2009 Randomized Motivational intervention plus 
NRT versus NRT plus self-help 
Intervention: 18 
Control: 22 
3 months Intervention: 22%, no 
difference from the control; 
but reduced cigarette 
consumption by ½ per day 





2009 Randomized Motivational intervention plus 
NRT vs. NRT plus usual care (2 




6 months Intervention: 9% 
Control: 10% 
Not statistically significant 
Biochemical 
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Table 3. Cont. 
Author Year Design Intervention 
Number of 
Subjects 
Follow-up Abstinence Rate 
Measure of 
Abstinence 
Tornero [119]  2009 Non-randomized Varenicline Intervention: 22 
No control 
6 months Intervention: 24%; adverse 
events and abstinence rate 
comparable in the general 
population 
Biochemical 
Vidrine [41]  2012 Randomized Cellular phone counseling plus 
usual care vs. usual care (NRT, 




3 months Intervention: 9% 
Control: 2% 
P = 0.005 
Biochemical 
Moadel [120]  2012 Randomized Facilitated group treatment plus 




3 months Intervention: 19% 
Control: 10% 
P = 0.11 
Biochemical 
Cui [121]  2012 Non-randomized Varenicline Intervention: 36 
No control 
12 weeks Intervention: 42%; adverse 
events and abstinence rate 
comparable in the general 
population 
Biochemical 
Manuel [122]  2012 Randomized Motivational intervention plus 
NRT versus prescribed advise 
(self-help materials discussed 
with therapist) plus NRT 
Intervention: 15 
Control: 15 
1 month Intervention: 20% 
Control: 0% 
P = 0.067 
Biochemical 
NRT–nicotine replacement therapy; CI–confidence interval. 
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A few conjectures can be derived from Table 3. First, the combination of tobacco cessation 
counseling (in person or by telephone) and use of NRT is still effective among HIV-infected tobacco 
smokers [113,115]. Other proposed strategies (i.e., motivational interview, facilitated group treatment) 
have not been found to add additional benefits compared to this usual approach. Second, the use of 
buproprion and varenicline is expected to yield similar abstinence rates with that in the general 
population. However, randomized controlled trials involving these newer pharmacotherapeutic agents 
are needed. 
6. Tobacco Control among Adolescents in the General Population 
Adolescent and adult smokers share some common barriers to tobacco cessation including nicotine 
dependence and depression. However, adolescent smokers also have some barriers to tobacco 
cessation that may be more influential to them than to adults. Parental smoking negatively influences 
smoking behavior among adolescents. A survey of 4,502 adolescents who lived in two-parent 
households showed that adolescents whose parents stopped smoking were one third less likely to be 
ever smokers than those whose parents were still smoking and that adolescent smokers were two times 
more likely to quit smoking if they had parents who quit [123]. Peer influence has also been 
demonstrated to greatly impact smoking behavior among adolescents. Transition to daily tobacco use 
by the 12th grade at school among 270 adolescents was associated with tobacco use among parents and 
close peers on multivariate analysis in one study [124]. Another study demonstrated that among 
adolescents who initiated smoking at an older age (13–14 years), tobacco use among peers was the 
major influence in contrast to those who initiated tobacco use at a much earlier age (11–12 years) 
where parental smoking was found to be more influential [125]. 
The strategies for tobacco control among adolescents and adults differ in some ways.  
Adolescent tobacco control programs rely heavily on addressing psychosocial factors that influence 
tobacco use among the youth. Thus, some programs are carried out with the participation of parents, 
schools and communities. Furthermore, adolescent tobacco control programs rely less on the use of 
pharmacotherapeutic agents like NRT [126].  
The main strategy for tobacco control among adolescents has been counseling. Compared to usual 
care (i.e., brief advice, self-help pamphlets) or no intervention, physician-delivered counseling is 
associated with a two-fold higher abstinence rate [126]. Despite this, it is estimated that only 42–55% 
of adolescents are counseled against tobacco use during clinic visits [127,128]. A meta-analysis found 
that five to eight counseling sessions were associated with significantly higher abstinence rates 
compared with control (5% increase). Nine or more counseling sessions did not increase this 
abstinence rate further [129]. 
Counseling facilitated in schools and other community settings by teachers, nurses, healthcare 
counselors and other volunteers, as exemplified by the Not-On-Tobacco (N-O-T) program sponsored 
by the American Lung Association [130], has been shown to be effective in promoting tobacco 
abstinence based on pooled data from four studies on N-O-T (odds ratio 1.77, 95% CI 1–3.11) [131].  
A meta-analysis done by Sussman showed 4–5% higher abstinence rates associated with classroom 
and school-based counseling compared with controls [129]. 
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Similar to the general adult population, a variety of theoretical models have been utilized in tobacco 
control counseling whether in the clinic, school, or community, including the transtheoretical model, 
motivational enhancement, cognitive behavioral therapy, and social-influence-oriented approach 
(Table 4). These models are frequently combined in tobacco control programs. A recent meta-analysis 
of 24 randomized controlled trials, comprising a total of 5,000 patients, showed superiority of the 
transtheoretical model (two studies analyzed) and motivational enhancement (11 studies analyzed) in 
achieving tobacco abstinence of at least six months (each with odds ratio of 1.7) [131]. Cognitive 
behavioral therapy (six studies analyzed), in this meta-analysis was not associated with a statistically 
significant result. This is in contrast with Sussman’s earlier meta-analysis [129] that showed cognitive 
behavioral therapy (17 studies analyzed) was associated with a statistically significant treatment effect 
of 3.9%. This study also showed that social-influence-oriented approach was also associated with a 
significantly higher abstinence rate compared with usual care. 
Table 4. Theoretical models used in smoking cessation counseling. 
Counseling models Theory 
Transtheoretical model 
of change [132,133]  
Smokers are classified in different stages: precontemplation (not intending to 
quit), contemplation (intending to quit within the next 6 months), preparation 
(intending to quit within the next 30 days), and recent action (tobacco cessation). 
Tobacco cessation counseling is then tailored based on this. Providers help 
smokers advance to the next stage until they ultimately quit. 
Motivational 
enhancement [126,134]  
Advantages and disadvantages of tobacco use/cessation are determined together 
with smokers’ beliefs and values in order to identify any uncertainties that 
smokers may have. These uncertainties are then focused on and smokers are then 
guided in making a detailed quit plan. 
Cognitive behavioral 
therapy [129]  
Detailed instructions on cognitive-behavioral self-monitoring and coping skills 
regarding tobacco cessation are given (i.e., reasons for tobacco use are 
determined and smokers are taught coping skills) 
Social-influence-
oriented approach [129]  
Strategies aimed at resisting social influences promoting tobacco use are 
emphasized (i.e., awareness of tobacco industry promotions and empowerment of 
teenagers to protest against them) 
Among adolescents, signs and symptoms of nicotine dependence develop first and herald the onset 
of tobacco addiction [135]. Adolescents also have a higher risk of becoming nicotine dependent 
compared with adults [18]. NRT’s are safe and well-tolerated by adolescents however, a number of 
studies have not found its use to be beneficial in this population. Moolchan et al. [136], compared 
NRT plus behavioral therapy with behavioral therapy alone among 120 adolescent smokers and found 
no statistically significant difference in abstinence rate at three months after study completion in either 
arm. Similarly, 30-day tobacco abstinence rate was comparable among 100 adolescent smokers 
assigned randomly to receive either NRT plus cognitive behavioral therapy versus cognitive behavioral 
therapy alone [137]. A recent meta-analysis by Grimshaw et al. [131], found no pooled treatment 
effect associated with the use of NRT in adolescents. For this reason, the Agency for Healthcare 
Research and Quality (AHRQ) does not recommend the use of NRT to be part of routine tobacco 
control programs among adolescents [126].  
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Likewise, the use of buproprion, an atypical antidepressant and tobacco cessation aid, has not been 
validated among adolescents. In a study conducted in Austria, the duration of abstinence was 
statistically longer among 11 nicotine-dependent adolescents who received buproprion compared to  
11 subjects who did not (78 versus 30 days) [138]. However, in a study conducted in the US among 
211 adolescent smokers, abstinence rates at 10 and 26 weeks did not statistically differ between those 
who received both nicotine patch and buproprion and those who received nicotine patch alone [139]. 
Similarly, Muramoto et al. showed that buproprion was only associated with a significantly higher 
abstinence rate at six weeks but not at 26 weeks among 312 adolescent smokers [140]. Pooled data 
from a meta-analysis by Grimshaw et al, failed to demonstrate statistically significant treatment effect 
with the use of buproprion [131]. In Muramoto’s study, although generally safe, buproprion use was 
associated with more headache and cough versus placebo [140]. Two suicide attempts occurred in the 
buproprion group, one in a patient with depression and probable eating disorder. At present, the AHRQ 
does not endorse the use of buproprion for tobacco control among adolescents. 
Other pharmacotherapeutic agents for tobacco cessation, such as varenicline, a nicotinic receptor 
partial agonist, have not been studied among adolescent smokers to date. A preliminary study on the 
safety of varenicline was conducted by Faessel et al. [141]. The majority of adverse events were 
similar to those found in adults; mild in intensity and included nausea, headache, and vomiting. None 
of the adverse events led to drug discontinuation or dose reduction.  
Tobacco control among adolescents is however, promising primarily because majority of adolescent 
smokers are willing to stop using tobacco. At least 77% of adolescent current smokers have made one 
or more serious tobacco cessation attempts [142]. Unfortunately, majority of these attempts are 
unplanned and unassisted [143] and hence, only 10% lead to sustained abstinence [144]. This rate of 
failed quit attempts, however, exceeds that in adults [143] and adolescent smokers enrolled in tobacco 
control programs are twice more likely to succeed than those who are not [129]. 
7. Tobacco Control among Pregnant Women in the General Population 
Factors that are associated with continued tobacco use during pregnancy include lower educational 
attainment, long tobacco use history (i.e., at least five years), having a partner who uses tobacco, poor 
coping skills, coexisting psychiatric problems, and exposure to secondhand smoke [94,145,146]. There 
are also barriers to tobacco cessation that may be unique to women in general that can certainly 
influence decision to quit; women in the luteal phase of menstruation tend to be more successful at 
tobacco cessation compared to women in the follicular phase [94].  
The main strategy used to promote tobacco cessation among pregnant women is also counseling. In 
a meta-analysis of 72 randomized controlled trials [147], the estimated pooled risk reduction 
associated with any form of counseling during any stage of pregnancy, although low, was significant at 
0.94 (95% CI 0.93–0.96). Counseling was also associated with reduced rates of low birthweight 
neonates (RR 0.83, 95% CI 0.73–0.95) and preterm births (RR 0.86, 95% CI 0.74–0.98) but not with 
neonatal intensive care unit admissions, very low birth weight neonates, stillbirths, perinatal or 
neonatal mortality. 
Similar counseling models as discussed previously are also utilized among pregnant smokers with 
varied success rates. In the same meta-analysis cited previously [147], cognitive behavioral therapy 
Int. J. Environ. Res. Public Health 2013, 10 2484 
 
 
was the most studied counseling model with 31 RCTs reviewed (RR 0.95, 95% CI 0.93–0.97), 
undoubtedly increasing the over-all risk reduction associated with counseling in general. Strategies that 
involved provision of financial incentives (e.g., vouchers amounting to at least $50 [148,149]) to 
participants who successfully stopped tobacco use produced the greatest risk reduction (RR 0.76, 95% 
CI 0.71–0.81). Although the use of financial motivation is promising, there are currently no studies on 
policy implications of undertaking such a strategy at the population level [147]. 
The use of NRT during pregnancy is controversial primarily due to teratogenicity concerns.  
In experimental studies, nicotine was capable of crossing the placenta as well as achieving 
concentrations in breast milk 2–3 times higher than in plasma [150]. In animal models, it has been 
associated with fetal central nervous system abnormalities, cardiac malformations, pulmonary 
hypoplasia, uteroplacental insufficiency, and sudden infant death syndrome [150,151]. In humans,  
it has been linked to negative birth outcomes as well. A Danish cohort study among 20,603 pregnant 
smokers was conducted to determine the effect of NRT during the first 12 weeks of pregnancy [152]. 
The prevalence of congenital malformation (especially musculoskeletal defects) was found to be 
statistically higher among pregnant women who used NRT compared to those who did not (relative 
prevalence ratio 1.61, CI 1.01–2.58). This result should, however, be interpreted with caution as the 
proportion of pregnant women who used NRT in this study was small (1.2%). Furthermore, the result 
may have been confounded by mismatched risk factors between groups [153]. Pollak et al. showed a 
probable link between nicotine exposure and negative birth outcomes when an interim analysis 
revealed a higher rate of negative birth outcomes among pregnant smokers who received NRT 
compared to those who did not [154]. Gaither et al, in another retrospective study, found that pregnant 
smokers who used NRT had twice the risk of having low birth weight babies (OR 1.95, 95% CI:  
1.10–3.46) while those who did not use NRT had less than twice the risk (OR 1.31, 95% CI:  
0.92–1.87) compared to nonsmokers [155]. The authors postulated that prescription of NRT was 
biased toward heavy pregnant smokers who may have also had difficulty with tobacco cessation.  
As a result of these studies, nicotine is currently classified as a category D drug (positive evidence 
of human fetal risk; maternal benefit may outweigh fetal risk in serious or life-threatening situations). 
Despite this, many groups, including the American College of Obstetricians and Gynecologists 
(ACOG) [156], recognize its utility especially among high risk pregnant women who fail to stop using 
tobacco after counseling. The ACOG states that NRT can be recommended to such women under close 
supervision and after comprehensive and informed discussion on the risk of tobacco use and NRT. 
This statement emphasizes the fact that the risk of continued tobacco use is evidently greater than the 
possible risk of nicotine to the fetus. On the same note, supporters of NRT use during pregnancy also 
argue that nicotine levels are similar or even lower in abstinent pregnant women using NRT compared 
with those who continue to smoke as nicotine metabolism is increased during pregnancy [151,157]. 
A pooled risk reduction of NRT for tobacco cessation did not reach statistical significance in a 
recent meta-analysis of six RCTs comprising 1,745 pregnant smokers (RR 1.33, 95% CI: 0.93–1.91) 
most likely due to low adherence rates to NRT (7.2 to 29%) [158]. Whether this low adherence is 
attributed to side effects or other factors was difficult to ascertain as those studies who reported side 
effects mentioned only 10–25% adverse events rates (e.g., headache, dizziness, fatigue, heartburn, 
nausea, vomiting). Nonetheless, the meta-analysis found no statistically significant difference in the 
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rates of miscarriage, stillbirth, premature birth, or low birthweight deliveries between groups that used 
NRT and those that did not. 
At present, there are no clinical trials on the use of buproprion or varenicline for tobacco cessation 
among pregnant women. Both are classified as category C drugs (animal studies show adverse fetal 
effects but no controlled human studies or no animal or human studies; weigh possible fetal risk versus 
maternal benefit). Prior studies on the safety of buproprion among depressed pregnant women found 
higher rates of spontaneous abortion among those who used buproprion compared to those who did not 
(15% versus 4%, p = 0.009) [159] while a later and larger study found no difference in the prevalence 
of congenital malformation between these two groups [160]. There are currently no human studies on 
varenicline use among pregnant women. 
An important issue to address in all tobacco cessation programs undertaken among pregnant women 
is whether these interventions lead to a significant postpartum abstinence rate once the main motivation 
for tobacco cessation is past [161,162]. Relapse rates range from 67–93% within the first postpartum 
year [145]. In the recent meta-analysis by Lumley, the over-all benefit of intervention on abstinence 
rates was only significant during pregnancy and up to five months postpartum [147]. These results 
imply that women are cognizant of the harms of tobacco use during pregnancy but not of the ill effects 
of passive smoking to the baby [145]. Counseling of parents about tobacco cessation during pediatric 
visits has been shown to be effective. A study that involved 2,901 mothers of newborns showed that 
mothers who received counseling postpartum had higher quit rates and lower relapse rates compared to 
those who only received hospital tobacco cessation pamphlets [163]. The same promising results were 
seen in other studies [164,165]. Counseling parents about tobacco cessation is currently recommended 
by the American Medical Association as part of the routine pediatric visit [166]. 
Pregnancy offers a special opportunity for clinicians to frequently promote tobacco cessation as 
clinic attendances increase significantly during the antepartum and postpartum periods. Despite this, 
only half of obstetricians are estimated to address tobacco cessation during each visit and only 28% 
discuss actual tobacco cessation interventions [167]. In a meta-analysis by Lumley et al., low intensity 
intervention consisting of physician-delivered verbal counseling alone was associated with a 
statistically significant risk reduction in continued tobacco use (RR 0.95, 95% CI: 0.93–0.96) [147]. 
8. Smoking among HIV-Infected Adolescents, Young Adults and Pregnant Women 
8.1. Lessons Learned from the General Population 
The average number of attempts at tobacco cessation increases with age and the majority of 
smokers stop using tobacco after several failed attempts [168]. Furthermore, it is estimated that 
mortality rates with tobacco cessation before the age of 35 years are similar to that of  
non-smokers [169]. Hence, it is crucial that tobacco cessation interventions are initiated as early as 
possible among adolescents, young adults and pregnant women. 
Tobacco cessation interventions conducted among adolescents and pregnant women have generally 
been successful (Table 5). They mirror strategies in the adult population with the exception of 
pharmacotherapy. An appreciable proportion of both adolescents [142] and pregnant women [38] also 
desire to quit. Physician-delivered counseling during clinic visits has also been generally successful in 
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these groups [126,147]. This is however an underutilized strategy as only at least half of obstetricians 
and pediatricians address tobacco cessation during office visits [127,128,168].  
Table 5. Tobacco cessation strategies used in the general population. 





OR 1.82 (95% CI: 1.66–2.00) vs. usual care [33]  
OR 1.4 (95% CI: 1.20–1.60) vs. pharmacotherapy alone [126]  
OR 1.7 (95% CI: 1.30–2.10) vs. counseling alone [126]  
Adolescents Counseling  OR 2.9 (95% CI: 1.47–4.35) vs. usual care [129]  
Pregnant 
women 
Counseling alone or 
counseling plus NRT 
Counseling alone: RR 0.95 (0.93–0.97) vs. usual care [158]  
NRT + Counseling: RR 1.33 (95% CI: 0.93–1.91) vs. usual 
care [158]  
NRT—nicotine replacement therapy; OR—odds ratio; RR—risk ratio; CI—confidence interval. 
8.2. Addressing the Problem  
A major obstacle in addressing this issue is the lack of studies on tobacco control among these 
vulnerable groups. Nevertheless, studies conducted in the general population can be extrapolated.  
The prevalence rates of tobacco use among HIV-infected adolescents, young adults and pregnant 
women are also considerably lower than that of older HIV-infected persons and approach that of the 
general HIV-uninfected adult population (Table 1). Therefore, addressing the problem of tobacco use 
among HIV-infected adolescents, young adults and pregnant women provides an early opportunity to 
stop the trajectory of tobacco use at its nascency in the HIV-infected population. HIV infection also 
enables clinicians to address tobacco use more frequently among infected adolescents, young adults 
and pregnant women as these groups are usually engaged in care and are seen more frequently in clinic 
compared to uninfected counterparts. Thus clinicians, including infectious disease providers, need to 
actively assess tobacco use among their patients, be knowledgeable about tobacco cessation 
interventions, and be able to explain to patients the added risk that tobacco use poses to them above 
that of non-HIV-infected smokers. Modern technology (i.e., tablet computers, iPad, mobile devices) 
can help in assessing tobacco use. For instance, in our HIV clinics, we conduct a twice yearly risk and 
needs assessment using iPads. The assessment includes questions on tobacco use and the patient 
answers the questions while waiting for their clinician in the examination room. Once the assessment 
is complete, a real-time print-out is then provided to the clinician who will assess the patient. This 
practice provides useful information regarding tobacco use, among others, and ensures that risk 
behaviors are identified and addressed in a busy clinic setting.  
The five A’s for treating tobacco use and dependence (Figure 2) can be used as a first step in 
addressing tobacco use with each clinical visit; Ask about tobacco use, Advise to quit, Assess 
willingness to quit, Assist with quitting, and Arrange follow-up [126]. This is a strategy endorsed by 
the US Department of Health and Human Services to ensure that every patient who uses tobacco is 
identified, advised to quit and offered concrete tobacco cessation intervention. Among adolescents,  
a sixth A is usually included, to enable clinicians to Anticipate the risk of tobacco use among 
adolescent nonsmokers by assessing peer and parental influence and discussing possibility of tobacco 
initiation. Anticipation of this risk should be extended to all nonsmokers regardless of age. 
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Figure 2. The 5 A’s of treating tobacco use and dependence. 
 
Adapted from: Fiore MC, Jaen CR, Baker TB et al. Treating Tobacco Use and Dependence: 2008 Update. 
U.S. Department of Health and Human Services 2008. Available at: http://www.ncbi.nlm.nih.gov/books/ 
NBK63952/.  
9. Conclusions 
HIV-infected persons have improved life expectancy in the HAART era, however, mortality rates 
remain higher than the general population and early-onset multimorbidity with non-AIDS defining 
illnesses is characteristic. Behavioral factors certainly contribute to this excess mortality and morbidity 
risk. The prevalence of tobacco use among HIV-infected persons is up to threefold higher than the 
general population. Due to shared pathogenic mechanisms with HIV infection, tobacco use magnifies 
the inherent risk of cardiovascular/peripheral vascular disease, ischemic stroke, lung and cervical 
cancer, and osteoporosis that HIV-infected persons have.  
HIV-infected adolescents, young adults and pregnant women are important targets for effective 
tobacco control programs. The cardiovascular and pulmonary risks associated with tobacco use are 
established early among adolescent smokers. Tobacco use during pregnancy also leads to a number of 
preventable maternal and fetal risks. At present, studies on effective tobacco control among these 
groups are lacking. 
Addressing tobacco use early among HIV-infected adolescents, young adults, and pregnant women 
also provides a doable and practical preemptive strike against the tobacco epidemic in the HIV-infected 
adult population. Since these groups are usually engaged in HIV-related care, providers can repeatedly 
offer tobacco cessation counseling and follow-up on failed tobacco cessation attempts. Thus, it is of 
fundamental importance that HIV care providers actively assess tobacco use among their clinic 
population and that tobacco control strategies are routinely and consistently implemented in the 
outpatient clinic.  
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